Depression Clinical Trials in Newark

View 143 new treatments for depression near you in Newark, NJ. Every day, Power helps over 527 depression patients connect with leading medical research.

ALTO-300 for Depression

Alto Neuroscience Clinic, Newark + 4 more

This trial is testing ALTO-300, a new medication, to see if it can make antidepressants work better for patients who are already taking them.

Verified

Recruiting
Phase 2
Est. 4 - 6 Weeks
Adam Savitz, MD, PhD
Study Director

Feedback Timing During Learning for TBI with Depression

Research Clinic, West Orange + 1 more

The goal of this proposal is to examine the influence of feedback timing on learning and brain function in individuals with moderate-to-severe traumatic brain injury (TBI), with and without depression.Show More

Verified

Recruiting

No Placebo Trial

N/A
Est. 6 - 12 Weeks
Ekaterina Dobryakova, PHD
Principal Investigator

Bupropion for Depression

Bausch Clinic, Bridgewater + 1 more

This trial tests a new treatment for children with depression. The effectiveness is measured by changes in depression symptoms. Fluoxetine has been shown to be effective in treating major depressive disorder in children and adolescents.Show More
Waitlist
Phase 4
Est. 6 - 12 Weeks
Johnson Varughese
Study Director

REL-1017 for Depression

Relmada Clinic, Princeton + 2 more

This trial tests if adding REL-1017 to current antidepressant treatments can better help people with Major Depressive Disorder. Participants will take their usual antidepressants plus either REL-1017 or another substance. The goal is to see if REL-1017 can improve their depression symptoms. REL-1017 (esmethadone) has shown potential rapid and sustained antidepressant effects in previous trials.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Marco Pappagallo, MD
Study Director

Psilocybin for Depression

Research Clinic, Princeton + 1 more

This trial is testing psilocybin, a substance from mushrooms, to see if it can help adults with depression who may not respond well to current treatments. Psilocybin works by affecting brain chemicals related to mood. Psilocybin has shown promise as a treatment for major depressive disorder and was designated as a breakthrough therapy by the FDA in 2019.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Bipolar Disorder in Youth

AbbVie Clinic, Neptune + 3 more

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director

Investigational Drug for Bipolar Depression

Sunovion Clinic, Princeton + 1 more

This trial is testing a new medication called SEP-4199 CR to see if it can help adults aged 18-65 who have depression from Bipolar I disorder. The study will compare the effects of the medication to see if it reduces symptoms of depression. SEP-4199 has shown antidepressant efficacy in a previous study for bipolar depression.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
CNS Medical Director
Study Chair

Psilocybin for Major Depressive Disorder - TRD

COMPASS Pathways Clinic, Princeton + 1 more

This trial is testing COMP360, a new treatment for adults who have not responded to other depression treatments. Participants will receive one of three doses of COMP360 along with psychological support. The goal is to see if this combination can help improve their depression symptoms.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

ALTO-203 for Depression

Alto Neuroscience Clinic, Princeton + 1 more

The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will receive ALTO-203 25 μg and 75 μg, as well as placebo. During the multiple-dose period, participants will receive either ALTO-203 25 μg, 75 μg , or placebo. Safety will be assessed over the single dose and 28-day multiple dose periods.Show More
Recruiting
Phase 2
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

NMRA-335140 for Bipolar Depression

Neumora Clinic, Princeton + 1 more

This trial is testing a new medication called NMRA-335140 to see if it can help adults with Bipolar II disorder who are experiencing major depression. The medication aims to improve mood and reduce feelings of depression.Show More
Recruiting
Phase 2
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Page 1 of 2

Frequently Asked Questions

How much do depression clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do depression clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across depression trials in Newark, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for depression patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Why are others applying to these studies?

  • I have tried two other drugs that didn't have any positive affect on my mental health and am hoping that trying out this trial will help me find a solution.

    M.A. Patient

    Depression Patient

  • I've tried many anti-depressants in my 45 year struggle with Major Depression. I'm hoping this study is the 'game changer'

    B.E. Patient

    Late-Life Depression Patient

  • I've tried more then 5 drugs for depression and it's very depressing frustrating when they do not work, or even help nothing, I'm still looking for that one or 2 that will help

    A.L. Patient

    Major Depression Patient